Frontiers in Probing Alzheimer’s Disease Biomarkers with Fluorescent Small Molecules

Yong Woong Jun,† Seo Won Cho,† Junyang Jung,‡ Youngbuhm Huh,‡ YoungSoo Kim,*§ Dokyoung Kim,*†‡∥⊥ and Kyo Han Ahn*†

†Department of Chemistry, Pohang University of Science and Technology (POSTECH), 77 Cheongam-Ro, Nam-Gu, Pohang 37673, Republic of Korea
‡Department of Anatomy and Neurobiology, College of Medicine,∥Center for Converging Humanities, and⊥Biomedical Science Institute, Kyung Hee University, 26 Kyungheedae-Ro, Dongdaemun-Gu, Seoul 02447, Republic of Korea
§Integrated Science and Engineering Division, Department of Pharmacy, and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea

ABSTRACT: Alzheimer’s disease (AD) is the most common form of dementia. The pathogenesis of the disease is associated with aggregated amyloid-β, hyperphosphorylated tau, a high level of metal ions, abnormal enzyme activities, and reactive astrocytes. This outlook gives an overview of fluorescent small molecules targeting AD biomarkers for ex vivo and in vivo imaging. These chemical imaging probes are categorized based on the potential biomarkers, and their pros and cons are discussed. Guidelines for designing new sensing strategies as well as the desirable properties to be pursued for AD fluorescence imaging are also provided.

1. INTRODUCTION
Alzheimer’s disease (AD), known as the most common type of dementia, is a global concern today. It is characterized by various pathological markers, including amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs), which are two of the main AD hallmarks. Fluorescence imaging probes are commonly used in clinical investigations and diagnosis of AD. Specifically, Aβ plaques and tau tangles can be readily stained by fluorescent chemicals such as thioflavins for microscopic imaging of brain tissues. Fluorescent chemicals that penetrate the blood–brain barrier (BBB) and target these misfolded proteins were radiolabeled, which became the most innovative chemical contribution to the diagnosis of AD. Before the discovery of Pittsburgh compound B (PiB), a benzothiazole analogue derived from thioflavin T, autopsy was required to confirm the presence of the misfolded proteins in the brain tissue for a definitive diagnosis of AD. Accumulation of Aβ plaques and tau tangles precedes brain atrophy at least for a decade. Although the correlation of Aβ plaque levels with cognitive deficits is weak and tau tangles are not AD specific, the two species still remain as gold standards for the early diagnosis of AD. New biomarkers have also been suggested, and diverse small-molecular fluorescent probes are being investigated. In this Outlook, we review the representative AD biomarkers and sensing strategies of fluorescent probes to visualize each of the biomarkers using one-photon or two-photon microscopy, hoping that scientific endeavors in this field could lead to new diagnosis methods at clinical research sites, in addition to providing powerful tools for basic research on this detrimental disease.

2. MISFOLDED AMYLOID-β SPECIES
Aggregated Aβ species are considered to be the key pathological marker of AD. Efficient detection of these species is of keen interest for elucidating fundamental aspects of AD. In the amyloidogenic pathway, cleavage of amyloid precursor protein (APP) by β-secretase produces the N-terminal ectodomain fragment APPsβ and the transmembrane fragment β-stub that is subsequently cleaved by γ-secretase to...
Figure 1. Biomarkers of Alzheimer’s disease and its relevance in the pathogenesis of the disease. (a) Amyloid-β proteins, (b) neurofibrillary tangles, (c) metal ions (Cu(II), Zn(II), Fe(II/III)), (d) γ-aminobutyric acid (GABA), and (e) monoamine oxidases.

Figure 2. Sensing strategies of AD biomarkers. Development of probes for (a) amyloid-β plaques, (b) neurofibrillary tangles, (c) metal ions (Cu(II), Zn(II), Fe(II/III)), (d) monoamine oxidases, and (e) astrocytes.
produce monomeric Aβ peptides, while α-secretase produces APPα and α-stub in the non-amyloidogenic pathway (Figure 1a). Twenty missense mutations in APP such as KM670/671NL (Swedish) lead to Aβ peptides of different lengths. Monomeric Aβ peptides aggregate into different higher order species of oligomers, fibrils, and plaques (Figure 1c). The oligomeric intermediates have attracted particular attention due to their higher neurotoxicity than the plaques. Oligomers bind to various synaptic receptors (e.g., NMDAR, PRPc, and AMPAR) modulating several signaling pathways and also activate the pattern recognition receptors (PRRs) of the innate immunity system that triggers an inflammatory response (Figure 1e).

**Design Strategies of Fluorescent Probes for Misfolded Amyloid-β Species.** The generally targeted Aβ species are in a cluster form of amyloids which have compact and homogeneous cross-β sheet structures, providing a hydrophobic environment in contrast to a hydrophilic outside. For this reason, a typical sensing strategy is to discriminate the contrasting environments by using environmentally sensitive dyes having intramolecular charge transfer (ICT) excited states. In hydrophilic media, these dyes show poor fluorescence due to the formation of twisted ICT (TICT) states which are generally nonemissive. However, these are strongly fluorescent in hydrophobic media since the TICT is less stabilized, and, instead, a planarized ICT (PICT) state

![A probe with a flexible π-conjugated backbone offers strong fluorescence enhancement with minimized background signal when it binds with Aβ plaques.](image)

**Figure 3.** Two-photon probes for detecting AD biomarkers. (a) Illustration of two-photon absorption, pulsed laser and focal point excitation. (b) Illustration of the distribution of amyloid-β plaques in the brain. (c−h) Two-photon amyloid-β probes: (c) 2E10, STB-8, PiB, (d) benzothiazole 4, (e) NIRFs, Aβ probe 5, (f) SAD-1, (g) CRANADs, and (h) QAD-1. (i) A two-photon dual probe for MAOs and amyloid-β plaques.
which is strongly emissive is preferred. Thus, dipolar dyes emit weakly outside Aβ plaques but strongly inside Aβ clusters, allowing us to detect Aβ plaques (Figure 2a). In addition, the intercalation-induced conformational restriction of dyes inside the plaques can cause additional fluorescence enhancement in general. Most of the known fluorescent probes for Aβ plaques are sterically not bulky and have a linear shape to interact with “aligned” hydrophobic amino acid substituents in the β-sheet structures of Aβ plaques. It is also known that hydrogen bonding can provide additional binding affinity.

The molecular probes for Aβ species have been developed in three stages (Figure 2a): (i) Charged structures, (ii) neutral donor–acceptor (D–A) dipolar structures with rigid backbone, and (iii) flexible π-conjugated backbone structures. In the 19th century, Congo Red (CR) was introduced as an Aβ plaque probe. The structural feature of CR is the acidic functional groups (−SO₃H). The hydrophilic functional group enhanced water solubility and binding affinity toward Aβ plaques, but significantly reduced their BBB uptake. Although CR’s poor BBB permeability was enhanced through the modification of the backbone structure and substitution moieties (ThT, Methoxy-04, and AOI-987), these cationic probes still showed moderate binding affinity toward Aβ plaques and slow clearance from the brain. A neutral version of probes such as PiB which was introduced later alleviated the limitations mentioned above. The neutral probes showed improved binding affinity, BBB penetration ability, and faster clearance kinetics compared to the charged probes. Lastly, introducing flexible vinylene units, -(CH=CH)n−, into a π-conjugated backbone provided an advantageous feature of minimizing the background signal. Rota-

ional motions at the π-conjugation backbone induced nonradiative decay, and restricted rotational motion in a congested environment of Aβ plaques led to enhanced fluorescence. Therefore, a probe with a flexible π-conjugated backbone offers strong fluorescence enhancement with a minimized background signal when it binds with Aβ plaques. The dicyanovinyl group, which is a well-known electron-acceptor and acts as a molecular rotor, can be found in DDNP and related D–A type dipolar dyes. An additional advantage of this approach is the bathochromic shift to the near-infrared (NIR) region by extending the vinyl units. In spite of the great efforts made in this field, however, still it is challenging to detect amyloid oligomers, in addition to detecting Aβ plaques with complete suppression of background signals as well as the very low level of Aβ plaques in blood samples.

Design Strategies of Two-Photon Absorbing Fluorescent Probes for Misfolded Amyloid-β Species. For imaging biological systems with fluorescent probes, use of the longer wavelengths, preferably in the far-red or NIR region, is beneficial to obtain minimal autofluorescence from innate biological species, reduced light scattering, deep tissue penetration, and less photobleaching. In the same vein, two-photon and multiphoton microscopes (MPM) have received increasing interest in recent years (Figure 3a). Generally, Aβ plaques in AD mouse models first appear in the deeper layer of the cortex (>500 μm depth) and then gradually spread out to the entire cortex (Figure 3b). Therefore, the deep-tissue imaging capability for the AD biomarker is crucial for in vivo studies of AD in the animal model at an early stage. Accordingly, fluorescent probes having efficient two-photon absorbing properties, which are expressed by two-photon absorption cross section (TPACS, σ) in the unit of GM (Göppert-Mayer), are highly desired along with far-red and NIR emission. A general design strategy for such probes is to extend the π-conjugated backbone of dipolar dyes that have electron-donor and -acceptor groups at the opposite ends. Unfortunately, however, extension of the π-conjugated backbone structure also increases the molecular size of probes, which in turn reduces their photo- and chemical stability, water solubility, BBB permeability, and degree of ICT, all of which are undesirable features. Thus, it is challenging to compromise these conflicting issues in order to develop TP probes with large TPACS values and longer absorption/emission wavelength.

Chang and co-workers found the 2E10 dye through screening of a fluorescent styryl dye library, but it had poor BBB penetration capability. In order to overcome this drawback, the structure was modified into neutral analogues, and eventually STB-8 was developed for in vivo two-photon imaging (Figure 3c). In 2013, Kim and co-workers reported a TP probe for Aβ plaques, SAD-1, by combining PiB and acedan that is a well-known TP dye. SAD-1 had a nanomolar level of dissociation constant (Kd = 17 nM) for the Aβ plaques and was used to construct in vivo two-photon 3D images (Figure 3f). The benzothiazole compound 4, a hybrid structure between PiB and STB-8, was developed as a PET tracer. A vinyl spacer between the two aryl groups was introduced to increase the molecular flexibility (Figure 3d). Munro and co-workers found that the elongation of the spacer in near-infrared fluorescence (NIRF) probes results in bathochromic shifts with larger TPACS values. Later, Ahn and co-workers reported a modified version, Aβ probe 5, which has a more rigid backbone structure and thus shows higher photochemical stability and also emits stronger fluorescence than the acyclic analogue. The Aβ probe 5 readily penetrated BBB and visualized Aβ plaques down to >300 μm depth using two-photon microscopy (Figure 3e). Moore, Ran, and co-workers reported curcumin derivatives as two-photon probes for Aβ plaques. Since curcumin has anti-inflammatory, antioxidant, and lipophilic action, which improve the cognitive functions of AD patients, it has been also used for the treatment of AD. However, bioimaging application of the curcumin derivatives was limited due to their low fluorescence quantum yields. To overcome this limitation, curcumin derivatives, CRANAD compounds, were prepared by converting the enolate moiety into the corresponding boron complex and replacing the aryl groups of curcumin with different aromatic substrates. The first boron complex CRANAD-2 displayed a significantly increased fluorescence in the NIR region; however, CRANAD-2 was not able to detect soluble Aβ species such as monomeric Aβ peptide and cerebral amyloid angiopathy (CAA). The second-generation boron-complexes, CRANAD-3 and CRANAD-28, displayed excellent fluorescent responses toward Aβ species including soluble Aβ monomers, dimers, and oligomers with high binding affinity (Figure 3g). Similarly, a quadrupolar type dye, QAD1, reported by Kim and co-workers showed high two-photon absorbing property (σmax = 420 GM) and dramatic fluorescence enhancement upon the binding with Aβ plaques (Figure 3h).

3. HYPERPHOSPHORYLATED AND AGGREGATED TAU PROTEINS

In healthy neurons, the microtubules are assembled and stabilized by tau proteins. During neurodegeneration, tau proteins are often found detached from the microtubules and
modified by multiple post-translational modifications, such as phosphorylation, proteolysis, and glycosylation in the intracellular region.43 In the case of AD, intra- and extracellular hyperphosphorylation of tau proteins and subsequent formation of NFTs are the key biomarkers for clinical diagnosis. Formation of hyperphosphorylated form of tau (p-tau) is favored in the AD brain due to the imbalance of kinases and phosphatases. P-Tau loses its binding affinity to microtubule assembly and disintegrates to form tau aggregates and eventually NFTs.46 The abnormal NFTs destroy a vital cell transport system, eventually leading to neuronal cell death.46 There is approximately a 4–8-fold higher level of p-tau proteins in the AD brain compared to that of age-matched healthy brain.47 Similar to amyloid plaques, NFTs exhibit a characteristic distribution pattern of growth from entorhinal cortex to hippocampus to neocortex.

**Design Strategies of Fluorescent Probes for Tau Protein.** To date, a few molecular probes for p-tau aggregates have been reported, and they were developed mainly based on two detection strategies: intercalation of probes into p-tau aggregates and electrostatic binding of probes containing zinc ion with the phosphate groups in p-tau aggregates (Figure 2b). The sensing strategy for NFTs is not as apparent as it is for Aβ aggregates, plausibly due to the less defined binding modes in the case of p-tau aggregates. The most challenging part in the approach using the intercalation with p-tau aggregate is to secure selective binding affinity toward p-tau aggregates over Aβ plaques. Most of the known probes for p-tau and Aβ plaques are structurally somewhat similar (Figure 2b). Therefore, the way to find hit compounds showing selective binding affinity for p-tau has been to rely on a random screening method. Recently, it was proposed that a distance of 13–19 Å between the donor and acceptor in the probes benefits NFTs selectivity, while a shorter distance favors Aβ plaques and that, among similar compounds, fused ring containing probes show higher selectivity for tau over Aβ fibrils.48 Okamura and co-workers evaluated over 2000 molecular probe candidates in search of those with higher binding affinity for NFTs over Aβ species, and eventually they found a series of aryl-quionline derivatives, the THK derivatives.49 Among them, THK-523 allowed noninvasive fluorescent signal enhancement through electrostatic interaction (Figure 2b).55 By using the same approach, Bai and co-workers developed CyDPA2 by replacing the dye part of BODIPY-1 with a NIR emitting cyanine dye.56 Since this approach utilizes selective and strong electrostatic interaction between phosphates group and zinc ion, the probes discriminated p-tau protein (EC50 = 9 nM) over non-phosphorylated tau protein (EC50 = 80 nM) and Aβ plaques (EC50 = 650 nM) in vitro assays.

To date, a few molecular probes for p-tau aggregates have been reported, and they were developed mainly based on two detection strategies: intercalation of probes into p-tau aggregates and electrostatic binding of probes containing zinc ion with the phosphate groups in p-tau aggregates.

### 4. HIGH LEVELS OF METAL IONS

Copper, zinc, and iron are essential metal ions for brain functions. Normal signaling involves a high level of Zn(II) (~0.3 mM), flooding over synapses, which activates Cu(II) to be released into the synapses (0.015–0.03 mM).57 Homeostasis breakdown of these metal ions is often observed during the neurodegeneration process in many brain disorders such as AD.57 Epigenetic alterations by environmental exposure and inadequate diet are reported to cause such dysregulation of metal ions.58 In the senile plaques of AD patients, higher concentrations of transition metal ions, particularly Cu(II) (>0.4 mM), Zn(II) (>1.0 mM), and Fe(III) (>0.9 mM), are found.59,60 Increased concentration of transition metal ions affects not only the complexation and stabilization of Aβ plaques but also aggravation of cellular oxidative stress by converting hydrogen peroxide to hydroxyl radical through the Fenton-like reaction: (i) Aβ-Cu(II) + H2O2 → Aβ-Cu(I) + •OH + H+; (ii) Aβ-Cu(I) + H2O2 → Aβ-Cu(II) + •OH + OH.18

**Design Strategies of Fluorescent Probes for Metal Ions.** To study the relationship between those metal cations and Aβ plaques, Lim and co-workers reported iminopyridyl chelates, L1 and L2-a/b, which bind with both Cu(II) and Zn(II) ions.61,62 These chelates are designed to interact with Aβ plaques after forming the complexes with the metal ions (Figure 2c). L2-b which has high stability in aqueous media detects metal-induced Aβ aggregates in vitro as well as in human neuroblastoma cells. Furthermore, they showed that the dual probes based on this approach could be used to probe Aβ aggregation control, metal chelation, and ROS regulation by mass, NMR, and biochemical analyses. However, L1 and L2-a/b seem to be not suitable for further fluorescence studies due to its poor fluorescent properties.

### 5. UPREGULATED MONOAMINE OXIDASES

Monoamine oxidases (MAOs) are found in the outer mitochondrial membrane of neuronal, glial, and other mammalian cells. MAOs catalyze the oxidative deamination action of monoamines.63 Cu(II) is a strong activator of MAO B.64 In 2009, Hamachi and co-workers reported BODIPY-1 containing binuclear Zn(II)-2,2’-dipicolylamine (DPA) moieties, which selectively detects p-tau with fluorescent signal enhancement through electrostatic interaction (Figure 2b).55 By using the same approach, Bai and co-workers developed CyDPA2 by replacing the dye part of BODIPY-1 with a NIR emitting cyanine dye.56 Since this approach utilizes selective and strong electrostatic interaction between phosphates group and zinc ion, the probes discriminated p-tau protein (EC50 = 9 nM) over non-phosphorylated tau protein (EC50 = 80 nM) and Aβ plaques (EC50 = 650 nM) in vitro assays.

To date, a few molecular probes for p-tau aggregates have been reported, and they were developed mainly based on two detection strategies: intercalation of probes into p-tau aggregates and electrostatic binding of probes containing zinc ion with the phosphate groups in p-tau aggregates.

4. HIGH LEVELS OF METAL IONS

Copper, zinc, and iron are essential metal ions for brain functions. Normal signaling involves a high level of Zn(II) (~0.3 mM), flooding over synapses, which activates Cu(II) to be released into the synapses (0.015–0.03 mM).57 Homeostasis breakdown of these metal ions is often observed during the neurodegeneration process in many brain disorders such as AD.57 Epigenetic alterations by environmental exposure and inadequate diet are reported to cause such dysregulation of metal ions.58 In the senile plaques of AD patients, higher concentrations of transition metal ions, particularly Cu(II) (>0.4 mM), Zn(II) (>1.0 mM), and Fe(III) (>0.9 mM), are found.59,60 Increased concentration of transition metal ions affects not only the complexation and stabilization of Aβ plaques but also aggravation of cellular oxidative stress by converting hydrogen peroxide to hydroxyl radical through the Fenton-like reaction: (i) Aβ-Cu(II) + H2O2 → Aβ-Cu(I) + •OH + H+; (ii) Aβ-Cu(I) + H2O2 → Aβ-Cu(II) + •OH + OH.18

**Design Strategies of Fluorescent Probes for Metal Ions.** To study the relationship between those metal cations and Aβ plaques, Lim and co-workers reported iminopyridyl chelates, L1 and L2-a/b, which bind with both Cu(II) and Zn(II) ions.61,62 These chelates are designed to interact with Aβ plaques after forming the complexes with the metal ions (Figure 2c). L2-b which has high stability in aqueous media detects metal-induced Aβ aggregates in vitro as well as in human neuroblastoma cells. Furthermore, they showed that the dual probes based on this approach could be used to probe Aβ aggregation control, metal chelation, and ROS regulation by mass, NMR, and biochemical analyses. However, L1 and L2-a/b seem to be not suitable for further fluorescence studies due to its poor fluorescent properties.

**5. UPREGULATED MONOAMINE OXIDASES**

Monoamine oxidases (MAOs) are found in the outer mitochondrial membrane of neuronal, glial, and other mammalian cells. MAOs catalyze the oxidative deamination action of monoamines.63 Cu(II) is a strong activator of MAO B.64 In 2009, Hamachi and co-workers reported BODIPY-1 containing binuclear Zn(II)-2,2’-dipicolylamine (DPA) moieties, which selectively detects p-tau with fluorescent signal enhancement through electrostatic interaction (Figure 2b).55 By using the same approach, Bai and co-workers developed CyDPA2 by replacing the dye part of BODIPY-1 with a NIR emitting cyanine dye.56 Since this approach utilizes selective and strong electrostatic interaction between phosphates group and zinc ion, the probes discriminated p-tau protein (EC50 = 9 nM) over non-phosphorylated tau protein (EC50 = 80 nM) and Aβ plaques (EC50 = 650 nM) in vitro assays.

To date, a few molecular probes for p-tau aggregates have been reported, and they were developed mainly based on two detection strategies: intercalation of probes into p-tau aggregates and electrostatic binding of probes containing zinc ion with the phosphate groups in p-tau aggregates.

4. HIGH LEVELS OF METAL IONS

Copper, zinc, and iron are essential metal ions for brain functions. Normal signaling involves a high level of Zn(II) (~0.3 mM), flooding over synapses, which activates Cu(II) to be released into the synapses (0.015–0.03 mM).57 Homeostasis breakdown of these metal ions is often observed during the neurodegeneration process in many brain disorders such as AD.57 Epigenetic alterations by environmental exposure and inadequate diet are reported to cause such dysregulation of metal ions.58 In the senile plaques of AD patients, higher concentrations of transition metal ions, particularly Cu(II) (>0.4 mM), Zn(II) (>1.0 mM), and Fe(III) (>0.9 mM), are found.59,60 Increased concentration of transition metal ions affects not only the complexation and stabilization of Aβ plaques but also aggravation of cellular oxidative stress by converting hydrogen peroxide to hydroxyl radical through the Fenton-like reaction: (i) Aβ-Cu(II) + H2O2 → Aβ-Cu(I) + •OH + H+; (ii) Aβ-Cu(I) + H2O2 → Aβ-Cu(II) + •OH + OH.18

**Design Strategies of Fluorescent Probes for Metal Ions.** To study the relationship between those metal cations and Aβ plaques, Lim and co-workers reported iminopyridyl chelates, L1 and L2-a/b, which bind with both Cu(II) and Zn(II) ions.61,62 These chelates are designed to interact with Aβ plaques after forming the complexes with the metal ions (Figure 2c). L2-b which has high stability in aqueous media detects metal-induced Aβ aggregates in vitro as well as in human neuroblastoma cells. Furthermore, they showed that the dual probes based on this approach could be used to probe Aβ aggregation control, metal chelation, and ROS regulation by mass, NMR, and biochemical analyses. However, L1 and L2-a/b seem to be not suitable for further fluorescence studies due to its poor fluorescent properties.
of amine neurotransmitters such as dopamine and serotonin, playing an important role in the metabolism of neurotransmitters in the central nervous system. MAOs oxidize the amine functionality of neurotransmitters, for example, dopamine, to the corresponding iminium ion, which undergoes hydrolysis to produce the corresponding aldehyde, which in turn is converted into homovanillic acid with the production of hydrogen peroxide and ammonia through other enzymatic processes. MAOs assist in maintaining the homeostasis of neurotransmitters in the brain, thereby supporting appropriate neurological and behavioral outcomes. Upregulated activity of MAOs causes excessive production of neurotoxic by-products such as hydrogen peroxide which promote neuronal dysfunctions of both psychiatric disorders and neurodegenerative diseases (Figure 1e). Dysfunction of MAOs is closely associated with AD, Parkinson’s disease, and Huntington’s disease. A high level of MAOs, particularly MAO-B, was observed in the AD brain. In 2012, Ahn and co-workers used a two-photon MAO probe, which, upon enzymatic reaction, produces a fluorescent dye that can also sense Aβ plaques, to monitor a close correlation between the MAO-B activity and accumulation of Aβ plaques upon aging. A further study is necessary to understand the close correlation and also to know whether the enzyme activity is associated with the progress of AD.

**Design Strategies of Fluorescent Probes for MAOs.** A conventional strategy to develop MAO probes is to utilize the enzymes’ oxidizing reactivity to amine neurotransmitters, which can induce subsequent chemical transformations with fluorescent changes (Figure 2d). In the development of MAO probes, two kinds of amine substrates for MAOs have been introduced to the electron-donor of ICT based dipolar dyes, which undergo enzymatic cleavage accompanied by fluorescence changes. In 2006, Wood and co-workers introduced (3-amino-propyloxy)arenes as the reactive substrates of MAOs. MAOs transform the propylamine moiety into the corresponding iminium ion, leading to the cleavage of the amine moiety. A different amine substrate, 4-aryloxy-1,2,3,6-tetrahydropyridine, was introduced by Castagnoli and Zhou groups. MAO-B oxidizes the tetrahydropyridine moiety into the corresponding dihydro-pyridinium intermediate, which subsequently undergoes a hydrolytic ether cleavage. In both cases, probes exhibited a turn-on type response due to the PET quenching effect of the amine moiety. By following similar approaches, several fluorescent probes for MAOs have been developed. But still those with practical utility are in strong demand. As mentioned above, Ahn and co-workers recently disclosed that the MAO-B activity is highly correlated with the accumulation of Aβ plaques. The MAO probe, upon enzymatic reaction, produced a two-photon absorbing dye, IBC 2, that is capable of visualizing Aβ plaques down to >600 μm depth in vivo imaging. The deep imaging capability of IBC 2 is notable, considering that the reported TP probes imaged Aβ plaques only down to ~300 μm. Moreover, IBC 2 allowed imaging of small amyloid depositions such as CAA surrounding of the blood vessels (Figure 3i).

**6. REACTIVE ASTROCYTES**

Recently, astrocyte-related neuropathology has gained high research interest for studying homeostasis in the AD brain, memory impair process, and AD diagnosis. Astrocytes perform many functions in the brain, including the support of the endothelial cells in forming the BBB, the provision of nutrients to the nervous tissue, the maintenance of ion balance, and the repair process in the brain. In the AD brain, astrocytes undergo prominent changes in morphology and gene expression, leading to the disruption of synaptic connectivity and imbalance of neurotransmitter homeostasis. Moreover, in the AD brain, astrocytes near Aβ plaques become reactive (Figure 1d). Reactive astrocytes produce more putrescine, a type of polyamine degraded from toxic molecules, which is degraded into γ-aminobutyric acid (GABA) by MAO-B. Also reactive astrocytes elevate the resting Ca(II) level and enhance the intercellular Ca(II) waves, all of which may potentially lead to enhanced release of various gliotransmitters containing GABA into the extracellular space. GABA released into the extracellular space inhibits neuronal activity and impairs memory abilities. As a result, monitoring of unusual behavior of astrocytes along with the inflammation factor is one of the key subjects for AD-related mechanism study as well as AD diagnosis.

**Design Strategies of Fluorescent Probes for Astrocytes.** Astrocytes can be selectively stained by using fluorescent antibodies against glial fibrillary acidic protein (GFAP), a calcium-binding protein S100 beta, excitatory amino acid transporters (EAAT1/2), and aldehyde dehydrogenase-1 family (ALDH1L1). Sulforhodamine 101 (SR101), a small molecular dye, was known to stain astrocyte selectively, but the detecting mechanism remains to be elucidated (Figure 2e). Staining astrocyte with SR101 is fast and gives bright fluorescence in the red region, but application to in vivo staining is limited for its high dose injection requirement and poor BBB permeability, which is plausibly due to the negatively charged character. Since then, no specific strategy to detect astrocytes has been reported, demanding further efforts in this subject.

**7. SUMMARY AND OUTLOOK**

In this Outlook, we have reviewed the detection strategies of fluorescent probes for AD biomarkers, along with a summary of AD biomarkers. Even though the fluorescence imaging techniques with molecular probes are still a ways from clinical application, the in vivo study for the disease in animal models with finely designed probes contributes to our understanding of the biology of AD. We summarized demands and perspectives of fluorescent molecular probes for AD biomarkers. For in vivo imaging application of AD biomarkers, small molecular probes should meet several criteria listed below.

(i) High selectivity toward the biomarker
(ii) Biocompatibility (sufficient aqueous solubility, cell permeability, and low toxicity)
(iii) Sufficient photostability
(iv) Notable photophysical property change after binding or reaction with biomarkers
(v) Excitation as well as emission wavelengths in the biological optical window  
(vi) BBB penetration  
(vii) Fast circulation in and clearance from the brain.

■ AUTHOR INFORMATION
Corresponding Authors  
*(Y.K.) E-mail: ykim@yonsei.ac.kr.  
*(D.K.) E-mail: dkim@khu.ac.kr.  
*(K.H.A.) E-mail: ahn@postech.ac.kr.

ORCID
Yong Woong Jun: 0000-0001-9339-1265  
YoungSoo Kim: 0000-0001-5029-7082  
Kyo Han Ahn: 0000-0001-7192-7215

Author Contributions  
*Y.W.J. and S.W.C. contributed equally to this work.

Notes  
The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS
This work was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) of Korea funded by the Ministry of Science & ICT (NRF-2018M3A9H3021707) and Basic Science Research Program through Korea NRF funded by the Ministry of Education (NRF-2018R1A6A1A03025124, NRF-2018R1D1A1B07043383). K.H.A. acknowledges the financial support from the Global Research Program (NRF-2014K1A1A2064569) through the Korea NRF funded by Ministry of Science, ICT & Future Planning. D.K. thanks Dr. Jonathan M. Zuidema (UC San Diego) for helpful discussion. Y.K. thanks DaWon Kim (Yonsei Univ.) for the kind support.

■ ABBREVIATIONS
AD, Alzheimer’s disease; Aβ, amyloid-beta peptide; APP, amyloid peptide precursor; BBB, blood–brain barrier; MRI, magnetic resonance imaging; fMRI, functional magnetic resonance imaging; PET, positron emission tomography; SPECT, single photon emission computerized tomography; NIR, near-infrared; OPM, one-photon microscopy; TPM, two-photon microscopy; MMP, multiphoton microscopy; CSF, cerebrospinal fluid; CAA, cerebral amyloid angiopathy; p-tau, hyper-phosphorylated tau peptide aggregate; SPION, Superparamagnetic iron oxide nanoparticles; USPION, ultra-small super-paramagnetic iron oxide nanoparticles; Gd, gadolinium; i.v., intravenous; i.p., intraperitoneal; TPACS, two-photon absorption cross-section; MAOs, monoamine oxidase; ROS, reactive oxygen species; Methoxy-X04, 1,4-bis(4’-hydroxytrityl)-2-methoxybenzene; FDDNP, 2-(1-(6-(2-fluoroethyl-(methyl)amino)-2-naphthyl)ethylidene)-malononitrile; DMSO, dimethyl sulfoxide; GM, Göppert-Mayer; HEPES, 4-(2-hydroxyethyl)-1-piperazine-ethane-sulfonic acid); BSA, bovine serum albumin; HSA, human serum albumin; RVG, rabies virus glycoprotein.

■ REFERENCES
(1) Scheltens, P.; Blennow, K.; Breteler, M. M. B.; de Strooper, B.; Frisoni, G. B.; Salloway, S.; Van der Flier, W. M. Alzheimer’s disease. Lancet 2016, 388, 505–517.  
(2) Masters, C. L.; Bateman, R.; Blennow, K.; Rowe, C. C.; Sperling, R. A.; Cummings, J. L. Alzheimer’s disease. Nat. Rev. Dis. Primers 2015, 1, 1056.  
(3) Nordberg, A. Towards early diagnosis in Alzheimer disease. Nat. Rev. Neurol. 2015, 11, 69–70.  
(4) Goedert, M.; Spillantini, M. G. A century of Alzheimer disease. Science 2006, 314, 777–781.  
(5) Yin, J.; Hu, Y.; Yoon, J. Fluorescent probes and bioimaging: alkali metals, alkaline earth metals and pH. Chem. Soc. Rev. 2015, 44, 4619–4644.  
(6) Owens, E. A.; Henary, M.; El Fakhri, G.; Choi, H. S. Tissue-Specific Near-Infrared Fluorescence Imaging. Acc. Chem. Res. 2016, 49, 1731–1740.  
(7) LeVine, H. Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999, 309, 274–284.  
(8) Ametamey, S. M.; Honer, M.; Schubiger, P. A. Molecular Imaging with PET. Chem. Rev. 2008, 108, 1501–1516.  
(9) Frisoni, G. B.; Fox, N. C.; Jack, C. R., Jr; Scheltens, P.; Thompson, P. M. The clinical utility of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010, 6, 67–77.  
(10) Varghese, T.; Sheelakumari, R.; James, J. S.; Mathuranath, P. S. A review of neuroimaging biomarkers of Alzheimer disease. Neurobiol. Aging 2013, 28, 239–248.  
(11) Klink, W. E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D. P.; Bergstrom, M.; Savitcheva, I.; Huang, G.-F.; Estrada, S.; Ausen, B.; Debgrinth, M. L.; Barletta, J.; Price, J. C.; Sandell, J.; Lopresti, B. J.; Wall, A.; Kovisto, P.; Antoni, G.; Mathis, C. A.; Längstroem, B. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann. Neurol. 2004, 55, 306–319.  
(12) Serrano-Pozo, A.; Frosch, M. P.; Masliah, E.; Hyman, B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspect. Med. 2011, 1, a001689.  
(13) Faller, P.; Hureu, C.; Berthoumieu, O. Role of Metal Ions in the self-assembly of the Alzheimer’s amyloid-beta peptide. Inorg. Chem. 2013, 52, 12193–12206.  
(14) Greenwald, J.; Riek, R. Biology of amyloid: structure, function, and regulation. Structure 2010, 18, 1244–1260.  
(15) Suh, Y.-H.; Checleer, F. Amyloid precursor protein, presenilins, and α-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s disease. Pharmacol. Res. 2002, 44, 549–555.  
(16) Müller, U. C.; Deller, T.; Korte, M. Not just amyloid: physiological functions of the amyloid precursor protein family. Nat. Rev. Neurosci. 2017, 18, 281–298.  
(17) Weggen, S.; Beher, D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer’s disease. Alzheimer’s Res. Ther. 2012, 4, 9.  
(18) Kepp, K. P. Bioorganic chemistry of Alzheimer’s disease. Chem. Rev. 2012, 112, 5193–5239.  
(19) Fandrich, M. Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. J. Mol. Biol. 2012, 421, 477–440.  
(20) Vargas, L.; Cerpa, W.; Muñoz, F.; Zanlungo, S.; Alvarez, A. Amyloid-β oligomers synaptotoxicity: the emerging role of EphA4/c-Ab1 signaling in Alzheimer’s disease. Biochim. Biophys. Acta, Mol. Basis Dis. 2018, 1864, 1148–1159.  
(21) Salminen, A.; Ojala, J.; Kauppinen, A.; Kaarniranta, K.; Suuronen, T. Inflammation in Alzheimer’s disease: amyloid-β oligomers trigger innate immunity defence via pattern recognition receptors. Prog. Neurobiol. 2009, 87, 181–194.  
(22) Nasica-Labouze, J.; Nguyen, P. H.; Sterpone, F.; Berthoumieu, O.; Buchete, N.-V.; Coté, S.; De Simone, A.; Doig, A. J.; Fuller, P.; Garcia, A.; Laio, A.; Li, M. S.; Melchionna, S.; Moussaud, N.; Mu, Y.; Paravastu, A.; Pasquali, S.; Rosenman, D. J.; Strodel, B.; Tarus, B.; Viles, J. H.; Zhang, T.; Wang, C.; Derreumaux, P. Amyloid β protein and Alzheimer’s disease: when computer simulations complement experimental studies. Chem. Rev. 2015, 115, 3518–3563.  
(23) Singha, S.; Kim, D.; Roy, B.; Sambasivan, S.; Moon, H.; Rao, A. S.; Kim, J. Y.; Joo, T.; Park, J. W.; Rhee, Y. M.; Wang, T.; Kim, K. H.;
Amyloid probe binding to Alzheimer and control brain: autopsy study of a new fibril formation and is inhibited by congo red.

ACS Central Science

Generation NIR fluorophores for tumor imaging and fluorescence-emission tomography imaging: application to Alzheimer disease mutations: potential factors in amyloid plaque formation.

Development of positron emission tomography imaging agent for Alzheimer disease patients.

In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe.

Fluorescent bodipy-based Zn(II) complex as a fluorescent probe for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer’s disease.

In vivo amyloid-beta imaging in preclinical Alzheimer’s disease.

Imaging Aβ plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered congo red derivative.

J. Neuroophthal. Exp. Neurol. 2002, 61, 797–805.

J. Am. Chem. Soc. 2009, 131, 6543–6548.

J. Am. Chem. Soc. 2013, 137, 6781–6789.
(57) Liu, G.; Huang, W.; Moir, R. D.; Vanderburg, C. R.; Lai, B.; Peng, Z.; Tatsi, R. E.; Rogers, J. T.; Huang, X. Metal exposure and Alzheimer’s pathogenesis. *J. Struct. Biol. 2006*, 155, 45–51.

(58) Zatta, P.; Drago, D.; Bolognini, S.; Sensi, S. L. Alzheimer’s disease, metal ions and metal homeostatic therapy. *Trends Pharmacol. Sci. 2009*, 30, 346–355.

(59) Kozlowski, H.; Luczakowski, M.; Remelli, M.; Valensin, D. Copper, zinc and iron in neurodegenerative diseases (Alzheimer’s, Parkinson’s and prion diseases). *Coord. Chem. Rev. 2012*, 256, 2129–2141.

(60) Spinnello, A.; Bonsignore, R.; Barone, G.; Keppler, B. K.; Terenzi, A. Metal ions and metal complexes in Alzheimer’s disease. *Curr. Pharm. Des. 2016*, 22, 3996–4010.

(61) Choi, J.-S.; Braymer, J. J.; Nanga, R. P. R.; Ramamoorthy, A.; Lim, M. H. Design of small molecules to target metal-β species and regulate metal-induced β aggregation and neurotoxicity. *Proc. Natl. Acad. Sci. U. S. A. 2010*, 107, 21990–21995.

(62) Savelieff, M. G.; DeToma, A. S.; Derrick, J. S.; Lim, M. H. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer’s disease. *Acc. Chem. Res. 2014*, 47, 2475–2482.

(63) Edmondson, D. E.; Binda, C.; Wang, J.; Upadhyay, A. K.; Mattevi, A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. *Biochemistry 2009*, 48, 4220–4230.

(64) Stalenheim, E. G.; von Knorring, L.; Orelan, L. Platelet monoamine oxidase activity as a biological marker in a Swedish forensic psychiatric population. *Psychiatry Res. 1997*, 69, 79–87.

(65) Maher, P.; Davis, B. J. The role of monoamine metabolism in oxidative glutamate toxicity. *J. Neurosci. 1996*, 16, 6394–6401.

(66) Dias, V.; Junn, E.; Mouradian, M. M. The role of oxidative stress in Parkinson’s disease. *J. Parkinsons Dis. 2013*, 3, 461–491.

(67) Gandhi, S.; Abramov, A. Y. Mechanism of oxidative stress in neurodegeneration. *Oxid. Med. Cell. Longevity 2012*, 2012, 428010.

(68) Youdim, M. B.; Bakhle, Y. S. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. *Br. J. Pharmacol. 2006*, 147, S287–S296.

(69) Teo, K. C.; Ho, S.-L. Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease. *Transl. Neurodegener. 2013*, 2, 19.

(70) Kim, D.; Baik, S. H.; Kang, S.; Cho, S. W.; Bae, J.; Cha, M.-Y.; Sailor, M. J.; Moon-Jung, I.; Ahn, K. H. Close correlation of monoamine oxidase activity with progress of Alzheimer’s disease in mice, observed by in vivo two-photon imaging. *ACS Cent. Sci. 2016*, 2, 967–975.

(71) Li, L.; Zhang, C.-W.; Chen, G. Y. J.; Zhu, B.; Chai, C.; Xu, Q.-H.; Tan, E.-K.; Zhu, Q.; Lim, K.-L.; Yao, S. Q. A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson’s disease models. *Nat. Commun. 2014*, 5, 3276.

(72) Richards, G.; Messer, J.; Waldvogel, H. J.; Gibbons, H. M.; Draganov, M.; Faull, R. L. M.; Saura, J. Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington’s disease revealed by quantitative enzyme radiography. *Brain Res. 2011*, 1370, 204–214.

(73) Kim, D.; Beck, S.; Jung, J. Monitoring of monoamine oxidases as biomarkers of disease and disorder. *Bull. Korean Chem. Soc. 2018*, 39, 277–278.

(74) Zhou, W.; Valley, M. P.; Shultz, J.; Hawkins, E. M.; Bernad, L.; Good, T.; Good, D.; Riss, T. L.; Klaubert, D. H.; Wood, K. V. New bioluminogenic substrates for monoamine oxidase assays. *J. Am. Chem. Soc. 2006*, 128, 3122–3123.

(75) Long, S.; Chen, L.; Xiang, Y.; Song, M.; Zheng, Y.; Zhu, Q. An activity-based fluorogenic probe for sensitive and selective monoamine oxidase-B detection. *Chem. Commun. 2012*, 48, 7164–7166.

(76) Domingues, H. S.; Portugal, C. C.; Socodato, R.; Relvas, J. B. Oligodendrocyte, astrocyte, and microglia crosstalk in myelin development, damage, and repair. *Front. Cell Dev. Biol. 2016*, 4, 71.

(77) Schreiber, B.; Romanelli, E.; Liberski, P.; Ingold-Heppner, B.; Sobotta-Brillout, B.; Hartwig, T.; Chandrasekar, V.; Johannsen, H.; Zeilhofer, H. U.; Aguzzi, A.; Heppner, F.; Kerschensteiner, M.; Becher, B. Astrocyte depletion impairs redox homeostasis and triggers neuronal loss in the adult CNS. *Cell Rep. 2015*, 12, 1377–1384.

(78) Verkhatsky, A.; Olabarria, M.; Noristani, H. N.; Yeh, C.-Y.; Rodriguez, J. J. Astrocytes in Alzheimer’s disease. *Neurotherapeutics 2010*, 7, 399–412.

(79) Jo, S.; Yarishkin, O.; Hwang, Y. J.; Chun, Y. E.; Park, M.; Woo, D. H.; Bae, J. Y.; Kim, T.; Lee, J.; Chun, H.; Park, H. J.; Lee, D. Y.; Hong, J.; Kim, H. Y.; Oh, S.-J.; Park, S. J.; Lee, H.; Yoon, B.-E.; Kim, Y.; Jeong, Y.; Shim, I.; Bae, Y. C.; Cho, J.; Kowall, N. W.; Ryu, H.; Hwang, E.; Kim, D.; Lee, C. J. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease. *Nat. Med. 2014*, 20, 886–896.

(80) Hol, E. M.; Pekny, M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. *Curr. Opin. Cell Biol. 2015*, 32, 121–130.

(81) Guo, D.; Zou, J.; Rensing, N.; Wong, M. *In vivo* two-photon imaging of astrocytes in GFAP-GFP transgenic mice. *PLoS One 2017*, 12, No. e0170005.

(82) Mrak, R. E.; Sheng, J. G.; Griffin, W. S. T. Correlation of astrocytic S100β expression with dystrophic neurites in amyloid plaques of Alzheimer’s disease. *J. Neuropathol. Exp. Neurol. 1996*, 55, 273–279.

(83) Karki, P.; Kim, C.; Smith, K.; Son, D.-S.; Aschner, M.; Lee, E. Transcriptional regulation of the astrocytic excitatory amino acid transporter 1 (EAAT1) via NF-κB and yin yang 1 (YY1). *J. Biol. Chem. 2015*, 290, 23725–23737.

(84) Yang, Y.; Vidensky, S.; Jin, L.; Jie, C.; Lorenzini, I.; Frankl, M.; Rothstein, J. D. Molecular comparison of GLT1+ and ALDH1L1+ astrocytes in astroglial reporter mice. *Glia 2011*, 59, 200–207.

(85) Nimmerjahn, A.; Kirchhoff, F.; Kerr, J. N. D.; Helmchen, F. Sulforhodamine 101 as a specific marker of astroglia in the neocortex in vivo. *Nat. Methods 2004*, 1, 31–37.